<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309008</url>
  </required_header>
  <id_info>
    <org_study_id>AP-TRPV1-PI-03</org_study_id>
    <nct_id>NCT02309008</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Multiple Dosing Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream After Transdermal Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amorepacific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety/tolerability and pharmacokinetics of&#xD;
      PAC-14028 cream after transdermal administration in healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/Tolerability (adverse events, abnormal vital signs, ECG test, clinical lab tests, Numerical pain recording scale)</measure>
    <time_frame>Day 1~9, at specified time for each tests</time_frame>
    <description>AE incidence pattern, abnormal findings in vital sign, ECG test, and clinical lab tests, Numerical pain recording scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Concentration of PAC-14028 in Blood; Cmax, AUC)</measure>
    <time_frame>Day 1: 0 ~ 16h ; Day 2~8: 0h ; Day 9: 0 ~ 96h</time_frame>
    <description>Concentration of PAC-14028 in Blood; Cmax, AUC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle cream, dermal administration, multiple dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 cream, dermal administration, multiple dosing, dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028</intervention_name>
    <description>Participants will receive PAC-14028 cream applied topically once a day for 9 days</description>
    <arm_group_label>drug</arm_group_label>
    <other_name>PAC-14028 cream 0.1%</other_name>
    <other_name>PAC-14028 cream 0.3%</other_name>
    <other_name>PAC-14028 cream 1.0%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Participants will receive vehicle cream applied topically once a day for 9 days</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Vehicle cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy men aged 19 to 65 years at the time of screening&#xD;
&#xD;
          2. Whose weight is 50 kg or more, but less than 90 kg, and whose body mass index (BMI) is&#xD;
             18.0 kg/m^2 or more but less than 27 kg/m^2&#xD;
&#xD;
               -  BMI (kg/m^2) = weight(kg) /{height(m)}^2&#xD;
&#xD;
          3. Who doesn't have skin disease, skin damage (including tatoos or scars), or excessive&#xD;
             hair in application area which can affect drug absorption&#xD;
&#xD;
          4. Who voluntarily decides study participation after receiving detailed explanation about&#xD;
             the study and fully understanding it and who provides written consent for compliance&#xD;
             with study requirement including proper contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Who has clinically significant medical history or diseases involving liver, kidney,&#xD;
             neurological system, respiratory system, endocrine system, urinary system,&#xD;
             cardiovascular system,skin, psychical disorders or blood tumor&#xD;
&#xD;
          2. Who has a history of hypersensitivity or allergies to any drug (aspirin, antibiotics,&#xD;
             etc)&#xD;
&#xD;
          3. Who has taken any prescribed drugs, herbal agents or crude drugs within 2 weeks before&#xD;
             study drug administration, or who has taken any over-the-counter (OTC) drugs or&#xD;
             vitamins within 1 week before the study drug initiation (Investigators will determine&#xD;
             his eligibility by considering the effect of the drug on his safety or pharmacokinetic&#xD;
             results in case other inclusion/exclusion criteria is satisfied.)&#xD;
&#xD;
          4. Who has drug abuse history or positive result at urine screening tests (cannabinoid,&#xD;
             opioid, amphetamine, cocaine, barbiturate, benzodiazepine)&#xD;
&#xD;
          5. Who has smoked within 3 months before study drug administration (Smoker who has&#xD;
             stopped smoking for more than 3 months before study drug administration is eligible to&#xD;
             participate)&#xD;
&#xD;
          6. Who has confirmed positive at serological tests (HBs antigen, HCV antibody and HIV&#xD;
             antibody)&#xD;
&#xD;
          7. Who consistently consumes alcohol&#xD;
&#xD;
          8. Who has participated in other clinical study within 8 weeks before study drug&#xD;
             administration (however, the last dosing day is considered as the end of clinical&#xD;
             study.)&#xD;
&#xD;
          9. Who has had bleeding or blood collection and donation over 400 mL within 8 weeks&#xD;
             before study drug administration&#xD;
&#xD;
         10. Who donated whole blood within 2 months before study drug administration, who donated&#xD;
             via plasmapheresis/plateletpheresis within 1 month before study drug administration,&#xD;
             or who received a blood transfusion within 1 month before study drug administration&#xD;
&#xD;
         11. Whose vital sign measured at sitting position after resting at least 3 minutes is as&#xD;
             following&#xD;
&#xD;
               -  Low blood pressure (Systolic pressure: less than 90 mmHg, Diastolic pressure:&#xD;
                  less than 60 mmHg)&#xD;
&#xD;
               -  High blood pressure (Systolic pressure: higher than 150 mmHg, Diastolic pressure:&#xD;
                  higher than 100 mmHg)&#xD;
&#xD;
         12. Who is determined ineligible for study participation by investigators for any reason&#xD;
             including clinical lab test and ECG results.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trials Center</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

